ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

eptinezumab

Also written as “Eptinezumab”, “ALD403” and “ALD403 (Eptinezumab)”.

Its studies are mostly in Migraine Disorders · Cluster Headache, led by 2 companies.

Drug pageEptinezumab: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 23, 202223 company-led studies, 4 open or runningNext primary completion: Mar 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
H. Lundbeckits history only223 open or runningphase 4since Feb 23, 2022Apr 16, 2012Mar 26, 2027phase 3 · NCT04965675
Dr George Medvedev11 open or runningphase 3since May 16, 2024May 16, 2024Mar 2028phase 3 · NCT06428838

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr George Medvedev only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named eptinezumabINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ALD403
  2. May 16, 2024First study: phase 3 study in Migraine DisordersFirst studyNCT06428838 · 102 planned · Canada

Ahead

  1. Mar 2028Primary completion: phase 3 study in Migraine DisordersNCT06428838

TargetBeta

CALCA →CALCB →read by rule
“Calcitonin gene-related peptide inhibitor”ChEMBL 37, by rule

Studies

The one study Dr George Medvedev leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06428838Migraine Disorders · Canada3By invitationMar 2028102

How it is read

Names in the registry

  • “Eptinezumab”, 17 entries
  • “ALD403”, 5 entries
  • “ALD403 (Eptinezumab)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.